ARK Genomic Revolution ETF (ARKG) Covered Calls

The ARK Genomic Revolution ETF is an actively managed fund that targets companies at the forefront of the genomics revolution. It invests in firms involved in DNA sequencing, gene editing, CRISPR technology, therapeutics, and molecular diagnostics. The fund seeks long-term capital growth by identifying leaders and enablers in multiomic technologies and programmable biology, aiming to capture the benefits of innovations that enhance the quality of human and other life.

You can sell covered calls on ARK Genomic Revolution ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ARKG (prices last updated Thu 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

The ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund that focuses on the convergence of healthcare and technology. Managed by ARK Invest, the fund seeks to provide exposure to companies that are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific advancements in genomics into their business. This strategy is benchmark-agnostic and emphasizes disruptive innovation across multiple sectors, including health care, information technology, and materials.

Core Business and Products

The fund's investment universe is centered on several key technological pillars. These include Next-Generation Sequencing, which allows for rapid and low-cost DNA analysis; Gene Editing and CRISPR, which enable precise alterations to the genetic code; and Targeted Therapeutics, which utilize genomic data to create personalized medical treatments. ARKG also invests in Bioinformatics and Multiomics, using artificial intelligence and big data to analyze complex biological systems. By holding a concentrated portfolio of high-conviction stocks, the fund aims to capture the entire value chain of the genomic revolution, from the companies developing the tools to the ones creating the actual cures.

Competitive Landscape

ARKG operates in a highly specialized and competitive field, facing pressure from both index-based genomic funds and broader biotechnology ETFs. The actively managed nature of the fund allows it to pivot toward emerging technologies faster than traditional passive products. Key competitors that trade on major exchanges and feature active options markets include:

1. iShares Genomics Immunology and Healthcare ETF: This fund tracks an index of companies involved in genomics and immunology, providing a more diversified and lower-cost alternative to ARK's active management.
2. Global X Genomics & Biotechnology ETF: Focuses specifically on companies that stand to benefit from advancements in genomic science, including gene editing and genomic sequencing.
3. iShares Biotechnology ETF: A broad-based competitor that provides exposure to the wider U.S. biotechnology sector, including many of the established pharmaceutical companies that ARKG may avoid in favor of smaller innovators.
4. CRISPR Therapeutics: While a holding in the fund, this company is also a competitor for investment capital in the gene-editing space, developing transformative gene-based medicines for serious diseases.
5. Illumina: A dominant player in the sequencing market that provides the hardware and software used by many other firms in the ARKG portfolio.

ARKG maintains its edge by leveraging its proprietary research ecosystem to identify "winner-take-most" opportunities in technologies that are often overlooked by traditional healthcare analysts.

Strategic Outlook and Innovation

The strategic future of the genomics sector is driven by the decreasing cost of DNA sequencing and the increasing precision of molecular diagnostics. As these technologies become more accessible, the industry is moving toward a future where healthcare is proactive rather than reactive. The companies within ARKG are focused on developing "programmable biology" solutions that can address previously untreatable genetic disorders. This includes the expansion of base editing and prime editing, which offer even more refined control over genetic modifications than original CRISPR methods.

Innovation is also accelerating through the integration of artificial intelligence and neural networks into drug discovery processes. By using AI to predict how different proteins will interact or how a specific gene therapy will perform, companies can significantly reduce the time and expense of clinical trials. Furthermore, the convergence of genomics with agricultural biology is opening new markets in sustainable food production and bio-materials. The fund continues to position itself at the intersection of these advancements, betting that the long-term deflationary impact of these technologies will fundamentally restructure the global healthcare economy.

Want more examples? ARKF Covered Calls | ARKK Covered Calls